Organosyn LTD

What Organosyn LTD does

Organosyn LTD (ТОВ «ОРГАНОСІН ЛТД») is a privately held Ukrainian pharmaceutical company founded in 1996 and headquartered in Kyiv at the Forum City Garden Business Center. The company develops, markets, and distributes prescription medications, over-the-counter drugs, medical devices, and dietary supplements, organized across four product categories encompassing approximately 50 SKUs under brand names such as CLATINOL, EZOLONG, ZOXY (Rx), CETLO, COMBIGRIP, RESPIX, Zotek (OTC), BRIOMOSS, EARICLEAN (medical devices), and PROBEEZ, INVITOL, URORUBIN (dietary supplements). Manufacturing occurs across facilities in 7 countries, indicating a multi-jurisdiction production footprint, while sales and distribution are concentrated through a vetted commercial partner network within Ukraine.

The business model centers on a single-country channel/reseller GTM motion. Organosyn recruits and qualifies commercial partners through a formal process involving document analysis, compliance verification, and audit procedures, then services those partners through a structured weekly order cycle (orders submitted Thursdays via dedicated email). The company addresses three primary customer segments: healthcare providers and pharmacists prescribing or recommending products, end patients/consumers accessing OTC and prescription medicines, and commercial distributors requiring reliable supply and transparent terms. Pricing is not publicly disclosed; product information is gated for healthcare professionals, and commercial terms are negotiated after a confidentiality agreement.

Organosyn's product portfolio spans multiple therapeutic areas including respiratory infections, skin infections, urinary tract conditions, pain management, antifungal treatment, and dietary supplementation. A 2025 partnership with Swiss innovator RhenecaVis added an osteoarthritis treatment line to the Ukrainian market, and an active 2025-2026 launch cadence indicates continued portfolio expansion. The company maintains a multi-channel marketing presence (website, LinkedIn, Instagram, Facebook, corporate news/RSS, and Kyiv-Mohyla Business School-affiliated training programs) and signals stable operations through 29 years of continuous activity, multi-country manufacturing, regulatory certification, and 26% staff tenure exceeding 15 years.

Name

Organosyn LTD

Legal name

ТОВ «ОРГАНОСІН ЛТД»

Website

https://organosyn.com.ua

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

1–10 employees

Short description

Organosyn LTD is a Ukrainian-founded (1996) pharmaceutical company that develops, markets, and distributes prescription medications, OTC drugs, medical devices, and dietary supplements across a four-category portfolio of approximately 50 brands, serving healthcare providers, patients, and vetted commercial distributors primarily in Ukraine with manufacturing in 7 countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

Keywords

• Prescription medications
• Over-the-counter drugs
• Dietary supplements
• Pharmaceutical manufacturing
• Medical devices

Headquarters

HQ city

Kyiv

HQ country

Ukraine

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Pharmaceutical Products: Organosyn generates revenue through the manufacture and sale of pharmaceutical products including prescription medications, over-the-counter medications, medical devices, and dietary supplements.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

Organosyn develops, manufactures, and distributes prescription medications, over-the-counter drugs, medical devices, and dietary supplements. Production is performed at certified facilities in 7 countries and the company's products are sold in Ukraine primarily through a network of vetted commercial partners and distributors using a structured weekly ordering process. The portfolio spans antibacterial tablets, antifungals, respiratory products, antispasmodics, NSAIDs, probiotics, ear-care medical devices, and iron/vitamin dietary supplements.

Product overview

Organosyn LTD is a pharmaceutical company established in 1996 operating from Ukraine with manufacturing facilities in 7 countries. The company offers four main product categories: (1) Prescription medications (Рецептурнi препарати) including CLATINOL®, EZOLONG®, FEDIN-20®, FIBRINAZA-10/20, FLAMIDASE® tablets, Mebsyn Retard®, NEOTRIZOLE®, Novox®, Ofor®, OMZOL powder, Protechon Fast®, Synmeton, Ursonost, and ZOXY; (2) Over-the-counter medications (Безрецептурнi препарати) including CETLO®, CETLO® PLUS, CLOTRIMAZOLE, COMBIGRIP products, COMBISPASM products, Flamidase Phytoplus, FLAMIDES gel, ORHANORIK, Protechon®, RESPIX products, and Zotek®; (3) Medical products (Медичні вироби) including BRIOMOSS SILVER and EARICLEAN spray; (4) Dietary supplements (Дієтичні добавки) including BRIOMOSS INTENSE, BRIOMOSS LOZENGES, EASYDO, FOREVIA MAXI, INVITOL, MELAFRESH, Normocycle®, Normomens®, ORGANOLAKT®, PROBEEZ® product line (DUO, FEMINA, IMMUNO, INTENSE, KIDS), Respix® Sinus, Santeferra, and URORUBIN. The company has over 25 years of experience and employs approximately 26% staff with more than 15 years tenure.

Differentiator

Problem solved

Functional benefit

Products and services

• Prescription medications (Рецептурнi препарати) Prescription-only pharmaceutical line including CLATINOL®, EZOLONG® (and EZOLONG-20/40), FEDIN-20®, FIBRINAZA-10/20, FLAMIDASE® tablets, Mebsyn Retard®, NEOTRIZOLE®, Novox®, Ofor®, OMZOL powder for solution, Protechon Fast®, Synmeton, Ursonost, and ZOXY (oral antibacterial Azithromycin 250/500 mg tablets for respiratory, skin, and sexually transmitted infections). Sold to pharmacies and healthcare providers via commercial partner network.
• Over-the-counter medications (Безрецептурнi препарати) OTC pharmaceutical line including CETLO® and CETLO® PLUS, CLOTRIMAZOLE (tablets and ointment), COMBIGRIP DEXA®, COMBIGRIP Hot Sip®, COMBIGRIP® tablets, COMBISPASM® and COMBISPASM® GASTROCOMFORT, Flamidase Phytoplus, FLAMIDES gel, ORHANORIK, Protechon®, RESPIX® L, RESPIX® SPRAY, RESPIX®, and Zotek® (dexibuprofen 200/300/400 mg film-coated tablets for mild-to-moderate pain). Targeted at end consumers via pharmacy and retail distribution.
• Medical devices (Медичні вироби) Medical device line including BRIOMOSS SILVER (silver-based formulation) and EARICLEAN spray (20 ml ear spray with sodium dioctyl sulfosuccinate, aloe vera extract, and sodium hyaluronate for earwax removal and ear mucosa hydration). Distributed via commercial partner network to pharmacies and healthcare providers.
• Dietary supplements (Дієтичні добавки) Dietary supplement line including BRIOMOSS INTENSE, BRIOMOSS LOZENGES, EASYDO, FOREVIA MAXI, INVITOL, MELAFRESH, Normocycle®, Normomens®, ORGANOLAKT®, PROBEEZ® family (DUO, FEMINA, IMMUNO, INTENSE, KIDS), Respix® Sinus, Santeferra (iron pyrophosphate/Lipofer®, L-ascorbic acid, cyanocobalamin, pteroylmonoglutamic acid), and URORUBIN (cranberry, sage, D-mannose for urinary tract support). Sold through retail and pharmacy distribution to end consumers.
• Pharmacovigilance service (Фармаконагляд) Pharmacovigilance function operated by Organosyn to monitor and report on the safety of its marketed pharmaceutical products, available to healthcare professionals and patients as part of the company's regulatory obligations.

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core.

• Kyiv-Mohyla Business SchoolcoreStrategic or Co-development Partner · 1 February 2026Organosyn partnered with Kyiv-Mohyla Business School for a large-scale corporate training program in 2026. The initiative focuses on expanding strategic thinking, deepening customer understanding, and learning to adapt quickly to dynamic market environments.
• RhenecaVis (Swiss innovation)coreStrategic or Co-development PartnerRhenecaVis represents Swiss innovation in osteoarthritis treatment that has been introduced to the Ukrainian market through Organosyn. This partnership brings innovative treatments for osteoarthritis patients in Ukraine.

Scale indicators3 records

Recent moves4 records

Expansion highlights5 records

Direct peers

• Borschagovsky Chemical-Pharmaceutical Plant: Kyiv-based pharmaceutical manufacturer producing finished dosage forms including generics and consumer health products. Direct Ukrainian competitor with similar manufacturing and B2B distribution focus.
• Farmak: Ukraine's largest pharmaceutical manufacturer, founded in 1925, producing a broad range of generic and branded medicines for domestic and export markets. Directly comparable to Organosyn in country, scale band, and broad Rx/OTC portfolio approach.
• Polpharma: Polish pharmaceutical manufacturer of generic Rx, OTC, and dietary supplements with strong CEE presence. Comparable to Organosyn in product mix including supplements and OTC, and as a regional manufacturer of similar size and origin market dynamics.
• Darnitsa Pharmaceutical Company: Major Ukrainian pharmaceutical producer established in 1930, with branded generics and OTC consumer health products. Closely comparable to Organosyn in geographic focus, broad therapeutic coverage, and partner-driven distribution.
• Arterium Corporation: Ukrainian pharmaceutical group formed from the merger of Halychpharm and Kyivmedpreparat, producing generic Rx and OTC medicines. Comparable to Organosyn in country of origin, product breadth, and distribution model.

Broad incumbents

• KRKA: Slovenian generic pharmaceutical manufacturer with strong CEE/CIS distribution presence and a wide Rx and OTC range. Comparable to Organosyn in generic generics + branded consumer health mix, and as a reference point for CEE/CIS distribution-led scale-up.
• STADA Arzneimittel: German-based European generics and consumer healthcare group with presence in CIS markets. Comparable to Organosyn in the consumer health and generics mix, and as a benchmark for partner-driven distribution in Eastern Europe.
• Teva Pharmaceutical Industries: World's largest generic drug manufacturer with a broad portfolio including OTC and specialty products. Comparable to Organosyn as the dominant global benchmark for pricing pressure and competition in generic Rx categories such as azithromycin.
• Gedeon Richter: Hungarian-headquartered pharmaceutical group active in CEE/CIS with branded generics and consumer health. Comparable as a regional incumbent whose CEE-focused distribution and product breadth resemble Organosyn's strategic positioning.
• Zentiva: European generic and specialty pharma company headquartered in Prague with a broad Rx and OTC portfolio across CEE and Western Europe. Comparable as a broader-market incumbent producing branded generics and consumer health products similar to Organosyn's lines.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/profile.php?id=61564418046183
• LinkedInlinkedin.com/company/organosyn
• Instagraminstagram.com/organosynltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Organosyn LTD